Articles On Pharmaxis (ASX:PXS)

Title Source Codes Date
Pharmaxis drug to be focus of new brain cancer study with grant from Charlie Teo Foundation

Proactive Investors PXS 6 days ago
Australian drug discovery to be studied in the US

A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

BiotechDispatch PXS 6 days ago
Here’s why Pharmaxis (ASX:PXS) shares are trending on the ASX

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

Kalkine Media PXS 1 week ago
Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer

PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Proactive Investors PXS 1 week ago
Capital Raisings Recap: Nearly $10 billion has already been raised in 2021

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Stockhead PXS 1 week ago
ResMed (ASX:RMD) shares fall after reporting flat sales in Q3 FY21

Summary Digital health behemoth ResMed has released its quarterly results for the March 2021 quarter reporting flat sales. The Company witnessed lower device sales and decreased demand for its ventilators due to COVID-19. However, str...

Kalkine Media PXS 1 week ago
Dr Boreham’s Crucible: Why is Pharmaxis’ valuation so ‘pitiful’? Karst Peak doesn’t know either

Inflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the register: Karst Peak Capital. The Hong Kong and Sydney based ‘contrarian’ fund manager is also a major holder in Neuren and Cyclopharm, and...

Stockhead PXS 2 weeks ago
Pharmaxis has multiple potential value inflection points with two drugs advancing in clinical trials

The clinical stage drug development company has boosted its balance sheet with a $4.4 million placement and the sale of Bronchitol Russian distribution rights for $2 million.

Proactive Investors PXS 2 weeks ago
Trading Places: Tolga Kumova has settled on a uranium play – Valor Resources (ASX:VAL)

If you want to know which ASX stocks fund managers and famous investors are putting their money into we’ve been keeping track of substantial holder buys (and sells). Trading Places is Stockhead’s recap of the substantial holder movements am...

Stockhead PXS 2 weeks ago
ScoPo’s Powerplays: Be cautious in May, but check out Volpara

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

Stockhead PXS 3 weeks ago
Pharmaxis sells Bronchitol rights in Russia and completes placement

Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors.

BiotechDispatch PXS 3 weeks ago
Pharmaxis’ Shares Jump ~9% on Sale of Distribution Rights in Russia

Source: Monster Ztudio, Shutterstock Summary Pharmaxis’ shares rose on the sale of Russian distribution rights for Bronchitol ®. The pharmaceutical research firm will get A$2 million distributor appointment fee. The drug maker is rai...

Kalkine Media PXS 3 weeks ago
Last Orders: ASX crosses 7,000 point mark

After a few near misses, the ASX has punched through 7,000 percentage points for the first time since the COVID-19 market crash. The ASX 200 rose by 0.70 per cent to 7,025 points while the ASX Emerging Companies Index rose by 0.56 per cent...

Stockhead PXS 3 weeks ago
Pharmaxis CEO talks $4.4mln fundraise and sale of distribution rights in Russia for Bronchitol

Proactive Investors PXS 3 weeks ago
Pharmaxis secures $4.4 million in placement to support ongoing myelofibrosis and skin scarring clinical studies

The company has also strengthened its balance sheet with the sale of Bronchitol Russian distribution rights for A$2 million with annual A$1 million cost savings.

Proactive Investors PXS 3 weeks ago
Lunchtime market update: ASX 200 gains traction

Source: Jirapong Manustrong, Shutterstock The ASX 200 is trading in the positive territory today. The benchmark lost some points in the first 15 minutes post market open. However, post the initial blip the market has steadily moved up. By...

Kalkine Media PXS 3 weeks ago
Australia…1 hour in… ASX200 up 18

ShareCafeAustralia…1 hour in… ASX200 up 18 ASX200 up 18 points (0.3%) to 6994   Brainchip (+18%); begins production of Akida AI Processor. Capral (+16%); has received a confidential nonbinding indicative proposal from Allegro Funds to acqu...

ShareCafe PXS 3 weeks ago
Last Orders: ASX finishes slightly in the green; tech gains 2 per cent & another IPO more than doubles

Today, the ASX finished slightly in the green, tech stocks were up over 2 per cent, and another IPO gained over 100 per cent. The ASX 200 rose 0.04 per cent, closing at 6,977 points. Meanwhile, the ASX Emerging Companies Index rose 0.36 per...

Stockhead PXS 3 weeks ago
Australia…1 hour in… ASX200 up 15

ShareCafeAustralia…1 hour in… ASX200 up 15 ASX200 up 15 points (0.2%) to 6989   A2Milk (+3%); upgraded by 2 brokers this morning. ANZ (-0.1%); ratings agency Fitch has upgraded its outlook on ANZ from negative to stable. Bingo (+8.2%); on...

ShareCafe PXS 3 weeks ago
Pharmaxis details world-first clinical trial of treatment to prevent wound and burn scars

Proactive Investors PXS 1 month ago
World-first trial for Australian company Pharmaxis

Pharmaxis (ASX:PSX) has announced a partnership to launch a world-first clinical trial that aims to stop scars from forming after trauma, particularly following burn injuries.

BiotechDispatch PXS 1 month ago
Last Orders: ASX back in the green as ‘risk on’ sentiment returns

Risk on sentiment has returned to the ASX. The ASX finished 0.78 per cent higher at 6,791 points although it peaked at 6,861 earlier today, which was nearly 2 per cent higher than the day before. The ASX Emerging Companies Index however los...

Stockhead PXS 1 month ago
Pharmaxis announces world-first clinical trial of wound and burn scars prevention treatment

The trial will investigate the potential of PXS‐6302 treatment to transform trauma recovery by blocking the underlying fibrosis causing scar tissue.

Proactive Investors PXS 1 month ago
Chiesi announces US launch of Pharmaxis' Bronchitol

Pharmaxis (ASX:PXS) has announced that its US partner Chiesi has launched BRONCHITOL (mannitol) in the US.

BiotechDispatch PXS 1 month ago
Market highlights and 5 ASX small caps to watch on Friday

US stocks dip as Treasury yields spike US stocks dipped from record highs on Thursday trading in the US, as US treasury yields spiked. The 10-year benchmark yield surged to 1.73%, rising from 1.68% yesterday. Despite the signal the Fed is s...

Stockhead PXS 1 month ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead PXS 1 month ago
Pharmaxis launches new trial of potential cancer therapy

Australian pharmaceutical company Pharmaxis (ASX:PXS) has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis.

BiotechDispatch PXS 2 months ago
Pharmaxis enrols first patient in its bone marrow cancer trial

Proactive Investors PXS 2 months ago
Here’s the latest development on Pharmaxis’ (ASX:PXS) cancer treatment

Summary ASX-listed Pharmaxis has enrolled the first patient for the clinical trial to evaluate a potential new treatment for bone marrow cancer. The study also includes a dose-escalation phase to select an optimum dose of PXS-5505. PX...

Kalkine Media PXS 2 months ago
Pharmaxis enrols first patient in clinical trial for PXS‐5505, a potential new treatment for bone marrow cancer myelofibrosis

“Its potential to modify the course of the disease by directly targeting bone marrow fibrosis will make PXS‐5505 an ideal monotherapy or adjunct to approved therapies in this indication,” says CEO.

Proactive Investors PXS 2 months ago
Pharmaxis begins exporting its cystic fibrosis drug Bronchitol® to the USA

Proactive Investors PXS 3 months ago
Pharmaxis (ASX:PXS) exports the first shipment of Bronchitol® to the US

Summary Australian pharmaceutical research player Pharmaxis has shipped the first batch of Bronchitol to the American city. Atlanta. The Company said its US distributor initiated a further US$3 Mn-milestone payment. Pharmaxis anticipa...

Kalkine Media PXS 3 months ago
Pharmaxis chalks up major milestone with export of first shipment to US of cystic fibrosis drug Bronchitol® following FDA approval

“This represents a proud and very rare achievement for a home‐grown pharmaceutical research company,” says CEO Gary Phillips.

Proactive Investors PXS 3 months ago
First export to the US triggers milestone payment for Pharmaxis

Pharmaxis (ASX:PXS) has triggered a US$3 million milestone payment after exporting the first shipment of its locally developed and manufactured drug BRONCHITOL (mannitol) to the US.

BiotechDispatch PXS 3 months ago
Pharmaxis receives milestone payment from US partner

Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

BiotechDispatch PXS 3 months ago
Pharmaxis Ltd (ASX:PXS) Obtains Milestone Payment from Chiesi Post FDA Approval

Summary Pharmaxis Ltd (ASX:PXS) has received a US$7 million milestone payment from Chiesi. The payment has been received post the FDA approval of Bronchitol® for treating cystic fibrosis. Pharmaxis  believes that the approval triggers...

Kalkine Media PXS 4 months ago
Pharmaxis boosts cash balance with US$7 million milestone payment from US licensee Chiesi following FDA approval of Bronchitol®

Pharmaxis is now advancing clinical development of a new cancer drug.

Proactive Investors PXS 4 months ago
Why the Pharmaxis (ASX:PXS) share price jumped 6% today

The Pharmaxis Ltd (ASX: PXS) share price is up today on the news it has received a substantial payment from a strategic partner. The Pharmaxis share price reached an intraday high of 9.9 cents in late morning trade, but has since pulled ba...

Motley Fool PXS 4 months ago
Pro Medicus (ASX:PME) Extends Footprint in North America with MedStar Health Deal

Summary Leading medical imaging company Pro Medicus Limited has signed a five-year deal with MedStar Health. With this contract, the Company’s Visage 7 platform would be deployed entirely to the public cloud. The Company plans for the...

Kalkine Media PXS 4 months ago
Something For Nothing

It is indeed possible to get something from nothing. Four small-caps appear to be defying the norms of capitalism. By Tim Boreham These companies are trading at close to cash backing, but are the discounts justified? “Something for nothing”...

FNArena PXS 4 months ago
Pharmaxis transformational Bronchitol FDA approval extends cash runway to fund Myelofibrosis trial

The company expects to announce receipt of milestone payments and the start of sales from its Bronchitol treatment in the near-term.

Proactive Investors PXS 5 months ago
Proactive Biotech Webinar attracts strong response

Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).

Proactive Investors PXS 5 months ago
Pharmaxis joins elite Australian club with US approval

Pharmaxis has become one of the small number of local life science companies to secure FDA approval of an Australian, developed, discovered and manufactured product.

BiotechDispatch PXS 6 months ago
Bhronchitol FDA Approval Transformative for Pharmaxis

ShareCafeBhronchitol FDA Approval Transformative for Pharmaxis Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced the United States Food and Drug Administration (FDA) has approved Bronchitol® (mannitol) as add‐on maint...

ShareCafe PXS 6 months ago
Pharmaxis CEO says US FDA approval for Bronchitol® is 'big day in company's history'

Proactive Investors PXS 6 months ago
Why the Pharmaxis (ASX:PXS) share price has rocketed up 48% today

Pharmaxis Ltd (ASX: PXS) today published a quarterly update in which the company reported three significant events. Consequently, the Pharmaxis share price has shot up 47.73% to 13 cents this morning. The pharmaceutical research company is...

Motley Fool PXS 6 months ago
Australia…One Hour In…ASX Up 6 Points

ShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); says the Ares takeover proposal implies a value of $1.85 a share. Trading @ $1.65.– IAG (-0.8%); CEO Mark Milliner to leave. Nick Hawkins new C...

ShareCafe PXS 6 months ago
Pharmaxis achieves gold standard as Bronchitol granted FDA approval for US market

Australian drug discovery will now be available for cystic fibrosis patients in the USA in a “transformational” event for the company with cash flow generated to take lead pipeline drug to end of phase 2 clinical trials.

Proactive Investors PXS 6 months ago
Pharmaxis secures US FDA approval for Bronchitol, sales to bankroll development of myelofibrosis drug candidate

In what has been described as a “transformational step” Pharmaxis (ASX: PXS) has collared United States Food and Drug Administration approval for its Bronchitol drug (mannitol) to be used in the country as an adjunct therapy for cystic fibr...

SmallCaps PXS 6 months ago
Pharmaxis receives $5 million R&D tax incentive as it progresses myelofibrosis treatment

The company is focused on the phase 1/2 clinical trial of its pan-LOX inhibitor PXS-505 in myelofibrosis and will use the tax incentive to progress the drug’s development.

Proactive Investors PXS 6 months ago